Specificity of treatment is mandatory in very old patients with hairy cell leukemia

Specifičnost lečenja je neophodna kod vrlo starih bolesnika sa leukemijom vlasastih čelija

Dragonir Marisavljević*, Olivera Marković†, Radmila Živković*

*Clinical Hospital Center “Bežanijska kosa”, Belgrade, Serbia; †Faculty of Medicine, University of Belgrade, Belgrade, Serbia

Abstract

Introduction. There are only a few available data about hairy cell leukemia (HCL) in very old patients. We presented three very different cases of HCL in very old patients diagnosed in a single center and discussed some epidemiological and therapeutical issues in such patients.

Case report. The first patient, 89-year-old, had symptomatic cytopenia and achieved sustained complete remission after cladribine treatment. The second patient, 89-year-old, had asymptomatic disease with stable full blood counts during a 3-year follow-up period in which watch-and-wait policy was adopted. The third patient, 82 years old, had two malignancies (HCL and presumably metastatic colorectal carcinoma) and his only treatment were occasional red blood cell transfusions and symptomatic therapy.

Conclusion. The presented illustrative examples confirm individualization of treatment is mandatory in very old patients with HCL.

Key words: leukemia, hairy cell; aged, 80 and over; therapeutics; prognosis.

Introduction

Hairy cell leukaemia (HCL) is an indolent neoplasm of small mature B lymphoid cells with oval nuclei and abundant cytoplasm with irregular projections (hairy) involving peripheral blood and diffusely infiltrating the bone marrow and splenic red pulp 1. HCL is characterized by splenomegaly, pancytopenia, and infiltration of the bone marrow with lymphocytes that have irregular cytoplasmic projections when identified in the peripheral blood 1. At the time of diagnosis, most patients manifested symptoms related to anemia, neutropenia, thrombocytopenia, or splenomegaly. Approximately 25% of patients manifested fatigue or weakness, 25% manifested infection, and 25% were present because of the incidental discovery of splenomegaly or an abnormal peripheral blood count 2. Blood film and bone marrow examination are essential for the diagnosis of HCL. Immunohistochemistry of the marrow trephine specimens should include CD20 and DBA44 3.

There are no available data about the incidence of HCL in very old patients. We presented three very different cases of HCL in very old patients and discussed some epidemiological and therapeutical issues in such patients.

Correspondence to: Olivera Marković, Clinical Hospital Center “Bežanijska kosa”, Bežanijska kosa bb, 11 000 Belgrade, Serbia.
Phone: +381 63 85 85 244. Fax: +381 11 3559 896. E-mail: dragano@ptt.rs
Case report

The first 89-year-old patient had the right neck femur fracture in January 2011 and was treated surgically. After the surgery, there were no complaints. Physical examination showed cardiac arrhythmia and arterial hypertension. His complete blood counts (CBC) showed pancytopenia: hemoglobin 121 g/L (normal range 130–180 g/L), white blood cells (WBC) 1.1 × 10^9/L (normal range 4–10 × 10^9/L), absolute neutrophil count (ANC) 0.6 × 10^9/L and platelets 37 × 10^9/L (normal range 1.6–7.2 × 10^9/L). Biochemistry findings were normal. Ultrasonography of the abdomen revealed enlarged spleen (165 × 61 mm). He was admitted to the Hematology Department and trephine bone marrow biopsy was performed. Bone marrow examination revealed diffuse/interstitial infiltration with lymphoid cells (Figure 1). The cells were CD20+, with oval, round nuclei with small nucleolus and abundant light-grey cytoplasm. The marrow reticular fibrosis was grade III. Morphologically, the diagnosis of HCL was established. The patient was treated in March 2011 with 2-chlorodeoxyadenosine (cladribine 0.14 mg/kg/day) iv infusion over two hours for 5 consecutive days. During and after the treatment period he had no infections, nor other complications. The complete remission was achieved. On the occasion of his last follow-up (January 2013), the patient felt well, without any complaints and with normal hematological findings.

The second 89-year-old patient showed up in March, 2011, with the one year history of pancytopenia. He had been suffered from diabetes mellitus type II for 10 years, without complications. His complete blood counts showed: hemoglobin 102 g/L, WBC 4.0 × 10^9/L, ANC 1.1 × 10^9/L and platelets 109 × 10^9/L. Other laboratory findings revealed elevated blood glucose (8.2 mmol/L – normal range 3.3–6.1 mmol/L). Ultrasonography of the abdomen showed enlarged spleen, 190 mm in diameter. Morphological examination of the bone marrow specimen led to the diagnosis of HCL, with the following immunophenotype: TdT-, CD3+, CD117-, MPO-, lysosime-, glycophorine A-, PAX5+, CD20+, CD3-, BCL2+, DBA44+, CD43-, IgD-, CD68-. Biochemistry findings were normal. Ultrasonography of the abdomen showed the enlarged spleen (180 mm in diameter) and the enlarged liver (180 mm in diameter) with numerous secondary deposits (about 25 mm in average diameter). These findings were confirmed by computed tomography (CT) scan. CT scan also showed the thickness of the right colon wall. The patient refused colonoscopy and biopsy of the liver tumor. Regarding such decision of the patient, we decided not to treat him with specific anti-HCL therapy. He occasionally received red blood cell transfusions. On the occasion of his last follow-up (January 2013), the patient was still alive.

The third 82-year-old patient was admitted to the Hematology Department in November 2011 with the history of pancytopenia from February 2011 when he had a surgical intervention due to acute appendicitis. He complained of weight loss, malaise and dizziness. He also suffers from hypertension and cardiomyopathy. Laboratory evaluation showed pancytopenia (hemoglobin 64 g/L, WBC 1.4 × 10^9/L, ANC 0.3 × 10^9/L, platelets 154 × 10^9/L) and elevated sedimentation rate (120 mm/h; normal range < 30/h). The trephine marrow biopsy showed infiltration with hairy cells with following immunophenotype: TdT-, CD34-, CD117-, MPO-, lysosime-, glycophorine A-, PAX5+, CD20+, CD3-, BCL2+, DBA.44+, CD43-, IgD-, CD68-. Biochemistry findings were normal. Ultrasonography of the abdomen showed infiltration with hairy cells with following immunophenotype: TdT-, CD34-, CD117-, MPO-, lysosime-, glycophorine A-, PAX5+, CD20+, CD3-, BCL2+, DBA.44+, CD43-, IgD-, CD68-. Biochemistry findings were normal. Ultrasonography of the abdomen showed the enlarged spleen (180 mm in diameter) and the enlarged liver (180 mm in diameter) with numerous secondary deposits (about 25 mm in average diameter). These findings were confirmed by computed tomography (CT) scan. CT scan also showed the thickness of the right colon wall. The patient refused colonoscopy and biopsy of the liver tumor. Regarding such decision of the patient, we decided not to treat him with specific anti-HCL therapy. He occasionally received red blood cell transfusions. On the occasion of his last follow-up (December 2012), the patient was still alive.

Discussion

HCL is one of the rarest types of leukemia. The overall incidence is around 3 cases in million people per year, with a marked male preponderance (4 : 1) 4. Over the past 30 years the incidence of this disease has not changed according to the largest population based study carried out on 3,104 HCL patients identified from 1973 through 2002 through the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program 5. The median age at diagnosis is about 50 years, although some national HCL registries reported higher median age value for onset of the disease 6,7. However, there are no precise literature data about incidence.
of HCL in elderly persons. In the largest study of HCL in Serbia so far, which included 46 patients, there were no patients older than 60 years. According to the report of Population Division DESA, United Nations, the patients older than 80 years belong to the so-called “oldest old” population, which is now about 1% of the total human population.

Therefore, we were very surprised when diagnosed three patients older than 80 years in our hospital in the last few years. We believe that this was only a coincidence, not a change in epidemiological pattern of the disease in our country. Beside older age, clinical presentation of HCL in our patients was common: men with pancytopenia, splenomegaly and infiltration of the bone marrow with CD20+/DBA.44+ lymphocytes.

There is no widely agreed system for staging HCL, as well as for assessing prognostic factors. Heavy bone marrow infiltration and a large spleen will result in maximal degrees of cytopenia. Anemia (hemoglobin < 100 g/L), neutropenia (ANC < 1.0 × 10⁹/L) and thrombocytopenia (platelets <100 × 10⁹/L) in any combination are associated with a relatively poor prognosis. An assessment of prognosis should include response to purine analogue therapy. The main indications for treatment are symptomatic cytopenias or painful splenomegaly. If a patient is asymptomatic and cytopenia is minimal, it is reasonable to adopt watch-and-wait policy. In our three patients we strictly followed current guidelines for the HCL management. The first patient with symptomatic cytopenia received specific therapy (cladribine) and achieved complete remission. In contrast, since the second patient appeared to be quite stable CBC during a 3-year follow-up period, we decided that active monitoring is the most appropriate clinical approach. In addition, this patient was currently 92 years old. The third patient had two malignancies (HCL and presumably metastatic colorectal carcinoma) and, therefore, his treatment was only supportive (occasional red blood cells transfusions) and symptomatic therapy. HCL has an increased risk of second tumors. The relative risk of second cancers reported in various series of HCL patients ranged from 0.95 to 4.33, but simultaneous presentation of HCL and solid malignancies is very rare. Simultaneous presentation of HCL and solid malignancy is exceptional and only a few cases have been described. It has been described synchronous occurrence of HCL with neuroendocrine colon carcinoma, HIV-negative Kaposi’s sarcoma and signet ring carcinoma of the stomach.

Conclusion

The presented cases are illustrative examples that individualization of treatment is mandatory in very old patients with hairy cell leukemia.

REFERENCES

1. Golembi HM, Catusky D, Goldie DW. Hairy cell leukemia: A clinical review based on 71 cases. Ann Intern Med 1978; 89(5 Pt 1): 677–83.
2. Flandrin G, Sigaux F, Sebahoun G, Bouffete P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. Semin Oncol 1984; 11(4 Suppl 2): 458–71.
3. Jones G, Perry-Jones N, Wilkins B, Else M, Catusky D. Revised guidelines for the diagnosis and management of hairy cell leukemia and hairy cell leukemia variant. Br J Haematol 2012; 156(2): 186–95.
4. Staines A, Cartwright R-A. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993; 85(4): 714–7.
5. Hsiuada M, Chen BE, Jaffe ES, Travis LB. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 2007; 99(3): 215–22.
6. Julisson G, Samuelsson H. Swedish Lymphoma Registry. Hairy cell leukaemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. Leuk Lymphoma 2011; 2(Suppl 2): 46–9.
7. Kristensson SY, Vålderus B, Agnarsson BA, Haraldsdottir V, Olafsson O, Johannesson GM, et al. Epidemiology of hairy cell leukaemia in Iceland. Hematol J 2002; 3(3): 145–7.
8. Gutiér M. The importance of the immune phenotype of leukemic cells in patients with hairy cell leukemia [thesis]. Belgrade: Faculty of Medicine, University of Belgrade; 1998. (Serbian)
9. Department of Economic and Social Affairs population Division. World Population ageing: 1950–2050. New York: United Nations; 2001.
10. Matusiel F, Benboubker L, Garembus M, Caillef B, Divine M, Sebban C, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003; 17(1): 45–51.
11. Else M, Dearden CE, Matteis E, Garcia-Talavera J, Robatiner AZ, Johnson S-A, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145(6): 733–40.
12. Valemis NS, Pinialidis D, Tsiambas E, Gakis C, Nakos G, Sambozitis D, et al. Synchronous occurrence of neuroendocrine colon carcinoma and hairy cell leukemia. J Gastrointest Cancer 2011; 42(3): 131–6.
13. Perminov-Junajevic M, Djunic I, Tomin D, Terjic T, Jakavic L, Sokic A, et al. Simultaneous Presentation of Hairy Cell Leukemia and Metastatic Signet Ring Carcinoma of the Stomach Diagnosed by Bone Marrow Biopsy. Appl Immunohistochem Mol Morphol 2011; 19(3): 279–82.
14. Aydin SO, Eskinazan AE, Akhi H, Ozgunlu M, Baslar Z, Soyas T. Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi’s Sarcoma of the lymph Node: A Diagnostic Challenge and a Rare Coincidence. Case Rep Oncol 2011; 4(3): 439–44.